Behavioral
Radiotherapy followed by chemotherapy
Radiotherapy followed by chemotherapy is a behavioral intervention with 5 clinical trials. Currently 1 active trials ongoing.
Total Trials
5
Max Phase
—
Type
BEHAVIORAL
Molecule
—
Success Metrics
Active Trials
1(20%)
Phase Distribution
Ph phase_2
2
40%
Ph phase_3
1
20%
Phase Distribution
0
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(3)
Other(2)
Detailed Status
unknown2
Not yet recruiting2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 22 (66.7%)
Phase 31 (33.3%)
Trials by Status
unknown240%
not_yet_recruiting240%
recruiting120%
Recent Activity
1 active trials
Showing 5 of 5
not_yet_recruiting
Outcomes of Definitive Radiotherapy for Bladder Cancer
NCT07503795
recruiting
Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI)
NCT06586892
not_yet_recruitingphase_3
Primary Radiotherapy In MEtastatic Lung Cancer
NCT07135882
unknownphase_2
Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
NCT02560441
unknownphase_2
Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma
NCT01667302
Clinical Trials (5)
Showing 5 of 5 trials
NCT07503795
Outcomes of Definitive Radiotherapy for Bladder Cancer
NCT06586892
Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI)
NCT07135882Phase 3
Primary Radiotherapy In MEtastatic Lung Cancer
NCT02560441Phase 2
Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
NCT01667302Phase 2
Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma
All 5 trials loaded
Drug Details
- Intervention Type
- BEHAVIORAL
- Total Trials
- 5